| Pt. no. | Gender | Eye | CNV location | CNV type | CNV cause | Follow-up (months) | Age (years) | PDT (no.) | Log(MAR) | ΔVA (lines) | PLD pre (μm) | PLD last (μm) | GLD pre (μm) | GLD last (μm) | CLD pre (μm) | |
| VA pre | VA last | |||||||||||||||
| 1 | F | OD, B | Subfov | Class | POHS | 18 | 11 | 3 | 0.7 | 0.3 | 4 | 1800 | 1800 | 1800 | 800 | 1800 |
| 2 | F | OS | Juxtafov | Class | POHS | 19 | 23 | 3 | 0.6 | 0.4 | 2 | 1400 | 2400 | 1400 | 2400 | 1400 |
| 3 | F | OS, B | Subfov | Class | POHS | 3 | 29 | 1 | 0.6 | 0.8 | −2 | 2100 | 3000 | 4600 | 1600 | 2100 |
| 4 | F | OD | Subfov | Class | POHS | 18 | 8 | 1 | 1.5 | 1.0 | 3 | 3800 | 5400 | 3800 | 3800 | 3800 |
| 5 | F | OD | Subfov | Class | POHS | 18 | 29 | 1 | 0.3 | 0.0 | 2 | 850 | 1200 | 900 | 600 | 900 |
| 6 | F | OD | Subfov | Class | POHS | 6 | 24 | 1 | 0.9 | 0.7 | 2 | 2000 | 2500 | 3000 | 2500 | 2000 |
| 7 | F | OD | Subfov | Class | POHS | 85 | 6 | 2 | 1.0 | 0.5 | 6 | 3800 | 4100 | 3800 | 4100 | 4000 |
| 8 | F | OS | Subfov | Class | POHS | 62 | 28 | 1 | 0.5 | 0.0 | 5 | 1100 | 2780 | 1900 | 1900 | 1100 |
| 9 | M | OD | Subfov | Class | POHS | 23 | 18 | 2 | 1.0 | 0.7 | 3 | 800 | 1500 | 800 | 600 | 800 |
| 10 | M | OS, B | Subfov | Class | Myopia | 23 | 13 | 3 | 0.8 | 0.6 | 2 | 2600 | 2700 | 800 | 900 | 800 |
| 11 | F | OS | Subfov | Class | Myopia | 80 | 31 | 1 | 0.5 | 0.3 | 2 | 1700 | 2800 | 2000 | 1500 | 1200 |
| 12 | M | OS, B | Extrafov | Class | myopia | 35 | 15 | 1 | 0.2 | 0.0 | 2 | 1100 | 1100 | 1000 | 600 | 900 |
| n = 12 | Mean (SD) | 32 (28) | 19.9 (8.8) | 1.7 (0.9) | 0.76 (0.31) | 0.48** (0.30) | 2.6 (1.9) | 1921 (985) | 2607** (1171) | 2150 (1274) | 1775 (1169) | 1733 (1062) | ||||
| 13 | F | OS | Subfov | Class | Toxo | 59 | 10 | 5 | 0.3 | 0.3 | 0 | 2600 | 4000 | 3200 | 2200 | 2300 |
| 14 | F | OD | Extrafov | Class | Toxo | 23 | 13 | 2 | 0.3 | 0.3 | 0 | 1500 | 2800 | 3200 | 1100 | 1700 |
| 15* | M | OS | Subfov | Class | MCP | 27 | 30 | 4 | 0.2 | 0.7 | −5 | 900 | 3300 | 900 | 1800 | 900 |
| 16† | M | OS | Subfov | Class | MCP | 41 | 28 | 4 | 0.4 | 1.5 | −11 | 500 | 4000 | 800 | 4000 | 500 |
| n = 16 | Mean (SD) | 34 (24) | 19.7 (8.7) | 2.2 (1.3) | 0.60 (0.35) | 0.49 (0.39) | 1.1 (4.1) | 1722 (864) | 2836** (1118) | 2119 (1251) | 1963 (1387) | 1625 (1300) | ||||
-
Mean values (SD) are indicated in bold. Mean values of the total cohort (n = 16) are shown below.
-
*Patient 15 received systemic steroid treatment during 3 months after first PDT.
-
†Patient 16 received long-term systemic steroid treatment and one intravitreal injection the day after first PDT.
-
**p>0.05 (paired two-sided Student t test).
-
B, bilateral choroidal neovascularisation; class, classic CNV subtype; CLD, neovascularisation lesion dimension; CNV, choroidal neovascularisation; fov, foveal; GLD, greatest linear lesion dimension; M/F, male/female; OD/OS, study eye, oculus dexter/sinister; PLD, pigment epithelial lesion dimension; Pt. no., patient number; Toxo, toxoplasmosis; VA, visual acuity.
